<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905398</url>
  </required_header>
  <id_info>
    <org_study_id>BrALL 01-08</org_study_id>
    <secondary_id>ANVISA</secondary_id>
    <secondary_id>25351732040200851</secondary_id>
    <nct_id>NCT00905398</nct_id>
  </id_info>
  <brief_title>Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</brief_title>
  <acronym>ALLPhi</acronym>
  <official_title>Estudo da eficácia do Nilotinibe Concomitante à Quimioterapia no Tratamento de Pacientes Com Leucemia linfoblástica Aguda Filadélfia Positiva recém-diagnosticada</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rony Schaffel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with acute lymphoblastic leukemia and positivity for the breakpoint cluster
      region-Abelson murine leukemia (BCR-ABL) protein or the Philadelphia chromosome have a poor
      prognosis with standard chemotherapy. The prognosis seemed to improve following the adition
      of imatinibe, a BCR-ABL inhibitor, to the treatment but still a substantial amount of
      patients relapse or progress during treatment.

      Nilotinib is a BCR-ABL inhibitor more potent than imatinib. It has been shown to be effective
      against most of the cells that bear mutations of the BCR-ABL protein leading to resistance to
      imatinibe.

      The investigators' hypothesis is that the addition of nilotinib to a standard chemotherapy
      for acute lymphoblastic leukemia (ALL) will translate into more rapid BCR-ABL reduction and
      effectiveness against imatinib-resistant clones leading to less relapses and better survival.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to excessive toxicity and low compliance to the protocol scheme.
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission</measure>
    <time_frame>Day + 21 and Day + 41</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular remission</measure>
    <time_frame>Every three months until three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Three times a week for the first 40 days than once weekly for the next 9 months than monthly for the next 2.1 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>400mg, Oral, Bid, Daily for three years</description>
    <arm_group_label>nilotinib</arm_group_label>
    <other_name>Tasigna</other_name>
    <other_name>AMN107</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Acute Lymphoblastic Leukemia (ALL)

          -  BCR-ABL positive positive by PCR (central Lab)

          -  No previous treatment for ALL except for corticoids and cyclophosphamide less than 600
             mg/m2

          -  Must be able to swallow tablets

          -  Lab results within normal limits (Potassium, Calcium, Magnesio, Phosphorus,
             Transaminases, Alkaline Phosphatase, Bilirrubine, Amylase, Lypase)

        Exclusion Criteria:

          -  Heart disease

          -  Interval QTc Fridericia &gt; 480 msec

          -  Coumadin use

          -  Pregnancy

          -  PS = 4

          -  Previous medical history of etilism or/and pancreatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rony Schaffel, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rio de Janeiro Federal University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nelson Spector, MD, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Rio de Janeiro Federal University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Belinda Simões, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>São Paulo University (Ribeirão Preto)</affiliation>
  </overall_official>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2009</study_first_posted>
  <last_update_submitted>July 7, 2015</last_update_submitted>
  <last_update_submitted_qc>July 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Rony Schaffel</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoblastic</keyword>
  <keyword>Acute</keyword>
  <keyword>Philadelphia</keyword>
  <keyword>BCR-ABL</keyword>
  <keyword>Nilotinib</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
    <mesh_term>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

